Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA
Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...